### Practitioner's Docket No. MPI98-021DV3

#### IN THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application. Kindly Cancel Claims 1-20; 22, 23, 29-31.

#### STATUS OF THE CLAIMS:

1-20 (cancelled herein)

- 20. A method of identifying a compound that modulates the expression of a gene encoding GLUTX, the method comprising the steps of:
  - a) contacting a cell expressing a gene with a test compound; and
- b) detecting the level of expression of the gene in the presence of the test compound, wherein a difference in expression in the presence of the test compound compared to expression in the absence of the test compound indicates that the test compound modulates expression of the gene.
  - 21. The method of claim 20, wherein the compound is selected from the group consisting of polypeptides, ribonucleic acids, small molecules, ribozymes, antisense oligonucleotide, and deoxyribonucleic acids.
  - 22. (cancelled herein)
  - 23. (cancelled herein)
  - 24. A method for modulating hexose uptake, the method comprising modulating the expression or activity of a gene encoding the amino acid sequence of SEQ ID NO:2.
  - 25. A method for treating a patient having a disorder associated with aberrant expression or activity of a gene encoding the amino acid sequence of SEQ ID NO:2, the method comprising administering a therapeutically effective amount of a compound that decreases the expression or activity of the gene.

# Practitioner's Docket No. MPI98-021DV3

- 26. The method of claim 25, wherein the compound is selected from the group consisting of polypeptides. ribonucleic acids, small molecules, ribozymes, antisense oligonucleotides, and deoxyribonucleic acids.
- 27. A method for treating a patient having a disorder associated with aberrant expression or activity of a GLUTX polypeptide comprising the amino acid sequence of SEQ ID NO:2, the method comprising administering a therapeutically effective amount of a compound that increases the expression or activity of the gene.
- 28. The method of claim 27, wherein the compound is selected from the group consisting of polypeptides, ribonucleic acids, small molecules, ribozymes, antisense oligonucleotides, and deoxyribonucleic acids.

# 29-31. (cancelled herein)

- 32. The method of claim 20, wherein the gene further comprises a sequence encoding an amino acid sequence selected from the group consisting of:
  - i) the amino acid sequence of SEQ ID NO:2, and
  - ii) at least 15 contiguous amino acids of SEQ ID NO:2.